Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 1999 December;51(12) > Minerva Ginecologica 1999 December;51(12):483-500

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Ginecologica 1999 December;51(12):483-500

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: Italian

Chemoresistance in ovarian cancer. State of art and perspectives

Katsaros D., Fracchioli S., Arese P., Enria R., Cassinelli P., Mingrone K., Piccinno R., Rigault De La Longrais I. A., Massobrio M.


PDF


Aim of this study was to provide a review of the basic mechanisms of drug resistance in ovarian cancer and novel strategies to modulate drug resistance. Relevant articles published through August 1999 were identified using the Medline data base. Publications identified by the search were reviewed and evaluated critically for their relevance to drug resistance in ovarian cancer. Ovarian cancer patients have high response rates to initial chemotherapy after cytoreductive surgery. However, most will develop resistance to chemotherapy during the course of their treatment. There are multiple mechanisms resulting in drug resistance. Strategies to modulate drug resistance include dose intensity, various pharmacologic agents, and gene therapy.

top of page